Cargando…

The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis

Various animal models showed that peroxisome proliferator-activated receptor (PPAR)γ agonists, when given as a gavage shortly preceding colitis induction, protect against inflammatory bowel disease (IBD). We have examined the effects of 16 days rosiglitazone treatment via the diet prior to dextran s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramakers, Julian D., Verstege, Marleen I., Thuijls, Geertje, Te Velde, Anje A., Mensink, Ronald P., Plat, Jogchum
Formato:	Texto
Lenguaje:	English
Publicado:	Kluwer Academic Publishers-Plenum Publishers 2007
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915631/ https://www.ncbi.nlm.nih.gov/pubmed/17510806 http://dx.doi.org/10.1007/s10875-007-9074-2

Ejemplares similares

Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus
por: Bragt, Marjolijn CE, et al.
Publicado: (2009)

Arachidonic Acid but not Eicosapentaenoic Acid (EPA) and Oleic Acid Activates NF-κB and Elevates ICAM-1 Expression in Caco-2 Cells
por: Ramakers, Julian D., et al.
Publicado: (2007)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

Rosiglitazone activation of PPARγ suppresses fractalkine signaling
por: Wan, Yihong, et al.
Publicado: (2010)

The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model
por: Guzeloglu, Mehmet, et al.
Publicado: (2012)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study
por: GÜNDOĞDU, Burcu, et al.
Publicado: (2020)

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
por: Wu, Yanqiao, et al.
Publicado: (2020)

Effects of Dietary Plant Sterols and Stanol Esters with Low- and High-Fat Diets in Chronic and Acute Models for Experimental Colitis
por: te Velde, Anje A., et al.
Publicado: (2015)

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012)

Retraction of “Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis”
por: Wu, Yanqiao, et al.
Publicado: (2021)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Plant Stanol Esters Lower Serum Triacylglycerol Concentrations via a Reduced Hepatic VLDL-1 Production
por: Plat, Jogchum, et al.
Publicado: (2009)

Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
por: Mao, Jing-Wei, et al.
Publicado: (2012)

PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice
por: Sun, Ying, et al.
Publicado: (2013)

Effects of a Plant Sterol or Stanol Enriched Mixed Meal on Postprandial Lipid Metabolism in Healthy Subjects
por: Baumgartner, Sabine, et al.
Publicado: (2016)

Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview
por: Smolders, Lotte, et al.
Publicado: (2017)

The effects of long-term almond consumption on whole-body insulin sensitivity, postprandial glucose responses, and 48 h continuous glucose concentrations in males and females with prediabetes: a randomized controlled trial
por: Gravesteijn, Elske, et al.
Publicado: (2023)

Amoxicillin Modulates ApoA-I Transcription and Secretion, Predominantly via PPARα Transactivation Inhibition
por: Tayyeb, Jehad Z., et al.
Publicado: (2019)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats
por: Naderali, Mohammad M., et al.
Publicado: (2012)

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
por: Konger, Raymond L., et al.
Publicado: (2019)

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
por: Cheng, Wing Yin, et al.
Publicado: (2016)

Non-Cholesterol Sterol Concentrations as Biomarkers for Cholesterol Absorption and Synthesis in Different Metabolic Disorders: A Systematic Review
por: Mashnafi, Sultan, et al.
Publicado: (2019)

Rosiglitazone, an Agonist of PPARγ, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2
por: Han, ShouWei, et al.
Publicado: (2007)

Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS
por: Jing, Xinyue, et al.
Publicado: (2016)

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers
por: Step, Sonia E., et al.
Publicado: (2014)

Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization
por: Hu, Jiamiao, et al.
Publicado: (2018)

Rosiglitazone-Mediated Activation of PPARγ Restores HO1 Expression in the Human Preeclamptic Placenta
por: Grimaldi, Brooke, et al.
Publicado: (2023)

Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial
por: van der Made, Sanne M., et al.
Publicado: (2015)

Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants
por: van der Made, Sanne M., et al.
Publicado: (2017)

Nutritional Interventions to Improve Asthma-Related Outcomes through Immunomodulation: A Systematic Review
por: van Brakel, Lieve, et al.
Publicado: (2020)

The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
por: Keledjian, Kaspar, et al.
Publicado: (2020)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Butyric Acid Added Apically to Intestinal Caco-2 Cells Elevates Hepatic ApoA-I Transcription and Rescues Lower ApoA-I Expression in Inflamed HepG2 Cells Co-Cultured in the Basolateral Compartment
por: Tayyeb, Jehad Z., et al.
Publicado: (2021)

Dietary Macronutrients Do Not Differently Influence Postprandial Serum and Plasma Brain-Derived Neurotrophic Factor Concentrations: A Randomized, Double-Blind, Controlled Cross-Over Trial
por: Gravesteijn, Elske, et al.
Publicado: (2021)

PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1
por: Zhang, Yunfang, et al.
Publicado: (2018)

Activation of PPARγ by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats
por: Mansour, Mahmoud, et al.
Publicado: (2009)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eg2ab77qel9kadlag1vmb27sfi